ReviewCurrent rheumatology reports2016
What Causes Lupus Flares?
Review in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials.Lupus science & medicine · 2020Trial
- Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.Rheumatology (Oxford, England) · 2020Trial
- Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.Arthritis & rheumatology (Hoboken, N.J.) · 2018Trial
- Anaphylactic Induction of Lupus Nephritis and Posterior Reversible Encephalopathy Syndrome Following Administration of Depo-Provera.Case reports in immunology · 2026Article
- IL-33 expands plasma cells, disrupts germinal centers, and increases autoantibody production in mice.Nature communications · 2025Article
- Characteristics of peripheral blood lymphocyte subsets in elderly patients with psoriasis.Immunity & ageing : I & A · 2025Article
- The fourth trimester and challenges for the lupus patient.EULAR rheumatology open · 2025Review
- Exploring the Role of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus: A Clinical Case Study and Comprehensive Review.Arthritis & rheumatology (Hoboken, N.J.) · 2025Review
- Major Systemic Lupus Erythematosus Exacerbation after Severe Clostridium Difficile Infection: A Case Report.Mediterranean journal of rheumatology · 2024Article
- Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits.Pharmaceutics · 2024Review
- Article
- Relationship of regional ultraviolet index data with rash and systemic disease activity in youth with childhood-onset systemic lupus: results from the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatric rheumatology online journal · 2024Article
- Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study.The Journal of rheumatology · 2024Article
- Article
- Article
- Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.Arthritis care & research · 2023Article
- The association of trauma with self-reported flares and disease activity in systemic lupus erythematosus (SLE).Rheumatology (Oxford, England) · 2023Article
- High serum immunoglobulin D levels in systemic lupus erythematosus: more to be found?Clinical rheumatology · 2023Article
- Pro-apoptotic Bax mRNA expression: A novel predictor for systemic lupus erythematosus disease flare-up.Archives of rheumatology · 2023Article
- A Framework to Overcome Challenges in the Management of Infections in Patients with Systemic Lupus Erythematosus.Open access rheumatology : research and reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, follows a chronic disease course, punctuated by flares. Disease flares often occur without apparent cause, perhaps from progressive inherent buildup of autoimmunity. However, there is evidence that certain environmental factors may trigger the disease. These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms. Uncontrolled disease flares, as well as their treatment, especially with glucocorticoids, can cause significant organ damage. Tight surveillance and timely control of lupus flares with judicial use of effective treatments to adequately suppress the excessive immune system activation are required to bring about long term remission of the disease. We hope that new clinical trials will soon offer additional effective and target-specific biologic treatments for SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.